This is a case study of five isolated orbital nerve inflammatory pseudotumor cases presenting with protrusion and visual acuity of the right eye. Optic disk edema was observed by ophthalmoscopy. Plain and contrast-enhanced magnetic resonance imaging (MRI) were used to examine the orbital fat and enlargement of the right optic nerve sheath along with orbital magnetic resonance imaging diagnostic test. The visual acuity (VA) of all the admitted patients was 1.5/20. All the patients reported attacks of retrobulbar pain and severe headache at fairly regular intervals. The patients on clinical examination were found to have protrusion, reduced visual acuity of the right eye with an ipsilateral afferent pupillary defect. There was no motility of the right eye and the exophthalmos of the right part was 27 mm. On examination, patients were diagnosed to have idiopathic orbital inflammation and received steroid therapy for 6 months. Thereafter, patients received surgical treatment to remove the superior wall of the orbit followed by cortisone therapy for a further 6 months. The follow-up examination of the patients for one year revealed a gradual improvement in the vision of all the patients. The VA of the right eye for all the patients was 6/20, and the exophthalmos was now around 19 mm. Thus, a dramatic response to surgery and steroid treatment was observed in all the patients.
Purpose: To investigate the effect of hydrazinocurcumin on a human vascular endothelial growth factor (VEGF)-induced corneal neovascularization in rabbit model. Methods: Murine corneal neovascularization (CorNV) was induced via two intrastromal implantations of VEGF polymer 2 mm from the limbus. Hydrazinocurcumin was administered topically on the cornea 4 times daily for 7 days. The therapeutic effects of hydrazinocurcumin were evaluated daily using slitlamp. At the end of the treatment, the corneas were harvested for H&E staining, masson trichrome staining, immuno-histochemical study, and semi-quantification reverse transcription polymerase chain reaction (RT-PCR) was utilized for measurement of inflammation-related molecules. Results: Topical application of hydrazinocurcumin had significant therapeutic effects on CorNV Hydrazinocurcumin extract treatment was more effective in suppressing CorNV in terms of vessel length and levels of cluster of differentiation 31 (CD31) proteins or angiogenesis-related genes such as VEGF, matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9). The average length of vessels in hydrazinocurcumin-treated group was only 17 % of that in the control group.Hydrazinocurcumin also inhibited inflammation more markedly by more effectively inhibiting mononuclear and polymorphonuclear cell infiltration into the corneal stroma and reducing levels of stromal cell-derived factor-1 (SDF1), tumor necrosis factor-alpha (TNFα) and macrophage inflammatory . In addition, the corneas of hydrazinocurcumin group had a more regular and compact architecture of collagen with thinner corneal thickness than those of the untreated group. Conclusion: Hydrazinocurcumin inhibited human vascular endothelial growth factor (VEGF)-induced rabbit corneal neovascularization and thus can potentially be used for its treatment.
Retracted: Zhan W, Zhu J, Zhang Y. Inhibition of corneal neovascularization by hydrazinecurcumin. Trop J Pharm Res 2016; 15(2):349-354
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.